App-Quantinova.ai

A phase II prospective clinical study of the sandwich protocol, VDLP combined with concurrent radiation and cisplatin in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.

Li Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

T-cell lymphoma

Cisplatin

Sandwich-like gemcitabine, dexamethasone, and cisplatin(GDP) chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, upper aerodigestive tract natural killer/T-cell lymphoma.

Shu Tian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

T-cell lymphoma

Cisplatin

CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).

Corinne Faivre-Finn - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Cisplatin

Randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small cell lung cancer patients: The NVALT-8 study.

Harry J.M. Groen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC - Outcomes based on chemotherapy subsets.

Heather A. Wakelee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.

Marcello Tiseo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Cisplatin

A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801).

Koji Kawaguchi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC).

Ramaswamy Govindan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Results of clinical study of induction chemoimmunotherapy (iCIT) in patients (pts) with non-small cell lung cancer (NSCLC).

Yuriy N. Lazutin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Randomized phase II trial (RENO): efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC). SLCG 10/02.

Mariano Provencio - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis.

Samer Ali Srour - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

Cisplatin

Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM).

Jose Manuel Trigo Perez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

Cisplatin

CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM).

Raffit Hassan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

Cisplatin

Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Anne C. Chiang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Cisplatin

First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).

Yuankai Shi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cisplatin

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.

Kwai Han Yoo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Phase 3 study of first-line crizotinib vs pemetrexedcisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).

Shun Lu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Fabrice Barlesi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

A phase I trial of certolizumab plus chemotherapy in patients with stage IV lung adenocarcinomas.

Paul K. Paik - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cisplatin

Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in Wolfram syndrome 1 (WFS1) gene.

Heather E. Wheeler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Testicular cancer

Cisplatin

Filters

3952 Abstracts